Result of General Meeting and Issue of Equity

RNS Number : 0602Y

Redx Pharma plc

28 February 2017

 

28 February 2017

REDX PHARMA PLC

("Redx" or "the Company")

Result of General Meeting and Issue of Equity

Redx, the drug discovery and development company, is pleased to announce that, at a General Meeting held earlier today, all the resolutions proposed, as set out in the Notice of General Meeting circulated to shareholders on 10 February 2017, were duly passed.

As a result 26,779,958 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") will be admitted to trading on 1 March 2017.

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue. Following admission of the New Ordinary Shares on 1 March, the Company's total issued share capital will comprise 126,477,914 Ordinary Shares. This number may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Redx Pharma Plc
Neil Murray, Chief Executive	T: [phone]
Karl Hård, Head of Investor Relations & Corporate Communications	T: [phone]
Cantor Fitzgerald Europe (Nomad & Joint Broker)	T: [phone]
Phil Davies / Michael Reynolds
WG Partners LLP (Joint Broker)	T: [phone]
Claes Spång / Chris Lee / David Wilson

About Redx Pharma Plc

Company website: redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

 

END

 

 

MSCTPMMTMBJTBIR